Several times a year, Bruce Mehlman releases a fascinating PowerPoint presentation filled with interesting nuggets about American politics and government. Mehlman, a Republican lobbyist with the bipartisan firm Mehlman Castagnetti Rosen & Thomas, is a University of Virginia Law School graduate and friend of the Crystal Ball.
Bruce Mehlman’s latest slide deck has his own out and in list. Highlights include: GOP civil war/Dem civil war; press conferences/tweet storms; opposition research/hacking; sustainability initiatives/onshoring manufacturing.
As President Trump takes office how will his Administration, together with a Republican-controlled Congress, address the seemingly rampant hacking and intrusions that happen with unsettling regularity?
We’re 75 hours out from President Trump’s inauguration, and Republican lobbyist Bruce Mehlman is bracing for an earthquake. In the latest installment of his quarterly slide-deck for clients, Mehlman puts some hard numbers to the new order that’s about to take hold in Washington.
2017 had been shaping up as a year focused on fixing the Affordable Care Act’s insurance markets, slowing prescription drug price hikes, expanding Medicaid, improving mental healthcare and spreading value-based payment and delivery. Suddenly there’s a new, more conservative agenda. And almost everything in healthcare is up in the air.
In the summer of 2013, as state and federal officials readied new insurance marketplaces created through the Affordable Care Act, millions of Americans started getting disquieting notices from their insurers. Health plans were being canceled because they didn’t comply with the law, often called Obamacare.
Six years into building its business around the Affordable Care Act, the nation’s $3 trillion health care industry may be losing that political playbook. Industry leaders, like many voters, were stunned by the election of Donald Trump and unprepared for Republicans’ plans to “repeal and replace” Obamacare.
Even with a presumably business-friendly president-elect in Donald Trump, drugmakers that have been battered by criticism over high prices in the past year are bracing for Republican and Democratic lawmakers to take aim at the industry.